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a  b  s  t  r  a  c  t
Background:  Measles  vaccine  in  early  infancy  followed  by a  dose  at 9  months  of age  protects  against
measles  and enhances  child  survival  through  non-speciﬁc  effects.  Little  is known  of immune  responses
in  the  short  or long  term after  booster  doses.
Methods: Infants  were  randomized  to receive  measles  vaccine  at 9 months  of age  (group  1)  or 4  and  9
months  of  age  (group  2). Both  groups  received  a boost  at 36  months  of age.  T-cell  effector  and  memory
responses  using  IFN- ELIspot and  cytokine  assays  and  antibody  titres  using  a haemagglutination-
inhibition  assay  were  compared  at various  times.
Results: Vaccination  at 4 months  of  age  elicited  antibody  and  CD4 T-cell  mediated  immune  responses  .Two
weeks  after  vaccination  at 9 months  of  age  group  2 had  much  higher  antibody  titres  than  group1  infants;
cell-mediated  effector  responses  were  similar.  At  36  months  of  age  group  2  antibody  titres  exceeded
protective  levels  but were  4-fold  lower  than  group  1; effector  and cytokine  responses  were  similar.
Re-vaccination  resulted  in  similar  rapid  and high  antibody  titres  in  both  groups  (median  512); cellular
immunity  changed  little.  At  48  months  of  age  group  2 antibody  concentrations  remained  well  above
protective  levels  though  2-fold  lower  than  group  1;  T-cell  memory  was  readily  detectable  and  similar  in
both  groups.
Conclusions:  An  additional  early  measles  vaccine  given  to  children  at 4 months  of  age  induced  a  pre-
dominant  CD4  T-cell  response  at 9 months  and rapid  development  of  high  antibody  concentrations  after
booster  doses.  However,  antibody  decayed  faster  in  these  children  than  in the  group  given primary  vac-
cination  at  9 months  of  age.  Cellular  responses  after  9 months  were  generally  insigniﬁcantly  different.. Introduction
In Africa the timing of the ﬁrst dose of measles vaccine at 9
onths of age is an uneasy compromise designed to minimize
nterference from maternal antibody and to provide protection for
he maximum number of infants [1]. Unfortunately some children
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of mothers who  have been vaccinated rather than naturally infected
with measles lose maternal antibody long before this age. As vac-
cine coverage has increased more infants have become susceptible
to measles at a younger age [2].
Two strategies have been proposed to overcome this prob-
lem. Recently expensive mass vaccination campaigns have been
deployed to increase coverage and provide an opportunity for two
or more doses of measles vaccine. Thus herd immunity has been
enhanced co-incidentally protecting unimmunized infants [3].
Open access under CC BY license.Another strategy is to immunize children twice in infancy. Such
a regimen when used in Guinea–Bissau resulted in high coverage,
high antibody concentrations, excellent protection against measles
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0% [6]. These studies used the Edmonston-Zagreb (E-Z) strain of
easles vaccine which produces higher antibody concentrations
han other measles vaccines when maternal antibody is present [7]
r when used to boost antibody [8].
Research in the U.S.A. has shown that cell mediated responses to
easles vaccine given to children at 6 months of age were similar
o those in children vaccinated at 9 or 12 months of age but anti-
ody responses were diminished by maternal antibody. However 6
onths after a boost at 12 months of age protective levels of anti-
ody were achieved in 86% of the youngest children while T-cell
roliferative responses changed little in any of the age groups [9].
accine effectiveness of an early two dose schedule during a large
easles epidemic in Florida was 99% [10].
Despite the widespread use of repeated mass measles re-
accination in Sub Saharan Africa little is known of the resulting
mmune responses, their short term kinetics or their duration in
frican children. Thus we compared cell mediated and antibody
esponses in Gambian infants at various time points after one or




This study took place in Sukuta, a peri-urban village in The Gam-
ia. The cohort of children, criteria for selection and site have been
escribed elsewhere [11].
Fig.  1 shows the design of the study, the number of children at
ach time point and the various immunological tests undertaken.
The  studies were approved by the local MRC  Scientiﬁc Commit-
ee and by the Joint Gambian Government/MRC Ethics Committee.
.2. Vaccines, vaccine schedules and follow-up
At 4 months of age infants were allocated using random num-
ers to receive either no measles vaccine (group 1) or a standard
ose of E-Z measles vaccine (group 2) consisting of 3700 plaque
orming units (Serum Institute of India, Pune) given intramuscu-
arly in the left upper arm. EPI vaccines including a 3rd dose of
epatitis B, DTP and Hib vaccines and a 4th dose of oral polio
accine were also given. At 9 months of age in addition to yel-
ow fever vaccine given in the other arm group 1 received their
rst dose of measles vaccine and group 2 their second dose. At
6 months of age of age both groups received another dose of
easles vaccine. In order to avoid frequent venous bleeds children
ere also randomised either to be tested for memory responses
t 9 months of age or effector responses at 9.5 months of age
details not shown). To assess safety home visits were conducted
hrice in the two  weeks following measles vaccination at 4 and 9
onths.
.3. Laboratory methods
Serology:  Measles haemagglutination-inhibiting (HAI) antibody
hich correlates strongly with neutralizing antibody [12] and is
uicker and easier to assay than the plaque reduction neutraliza-
ion assay, was measured by use of Chlorocebus Aethiops red blood
ells (Barbados Primate Research Centre) as previously described
13]. The sensitivity of the assay was 15.6 mIU/ml and the mini-
um detection level 31.2 mIU/ml. Results were expressed as log2
nits or as reciprocal titres. We  deﬁned the protective level of HAI
easles antibody as a titre of log2 ≥ 3 which equates to 125 mIU
12].
Ex vivo measles effector cell assays: After separation of blood on
ymphoprep PBMC were used in the ex vivo interferon-gamma0 (2012) 2543– 2550
(IFN-) ELIspot assay as previously described [14]. The cells were
infected for 2 h with Edmonston (E-D) wild type measles virus or
E-Z measles vaccine virus which had been grown for 3 days on a
culture of Vero cells in RPMI/10% Foetal Calf Serum (R10F). The mul-
tiplicity of infection was  0.1 and 1.0 for the two strains respectively.
The infected cells were then washed and plated in duplicate at 105
cells/well in R10 with 10% AB serum (R10AB, Sigma). Control PBMC
were mock infected with R10F harvested after culture of uninfected
Vero cells for 3 days.
In  addition duplicate wells containing 105 PBMCs were also
stimulated with a pool of overlapping 20-mer measles fusion pep-
tides (NMI Peptides) dissolved in normal saline and 0.4% DMSO
and used at a ﬁnal concentration of 2 g/ml in R10AB. Control cells
were incubated in medium containing 0.02% DMSO which was the
same concentration as that in the test wells. Phytohemagglutinin
(5 g/ml) was  used as a positive control.
Spots were counted using the AID ELIspot plate reader (Autoim-
mune Diagnostika). The mean number of spots in the duplicate
wells of the negative control was  subtracted from the mean spot
count in the positive wells; an assay with a control value of ≥50
spots per well was regarded as invalid.
Measles memory cell assays: As described previously 106 PBMC
were cultured for 10 days in R10AB with 105 UV  irradiated PBMC
infected with measles virus [15] or with pooled measles nucleo-
protein or fusion peptides as described above. Controls consisted
of PBMC mock infected with Vero cell medium and treated in the
same way  as above.
Intracellular cytokine staining (ICS): Following stimulation, cells
were permeabilised and stained for ﬂow cytometry analysis as pre-
viously described [13]. The staining panel used at 9 and 9.5 months
was anti-CD8 FITC, anti-CD4 PE, anti-CD69 PerCP and anti-IFN-
APC. At 18 months, the panel was  anti-IFN- FITC, anti-CD4 PE,
anti-CD8 PerCP and anti-IL-2 APC. All antibodies were supplied by
BD Biosciences.
Cytokines in plasma or supernatants: Plasma was frozen at −40◦ C
until assayed using the Bio-Plex 200 Suspension Array system (Bio-
Rad) according to the manufacturer’s instructions.
FOXP3 mRNA expression: RNA was extracted from whole blood
collected in Paxgene tubes (PreAnalytix, QIAGEN) and frozen at
−40◦ C until RNA extracted. RNA was reverse transcribed into
cDNA using 1 M oligo-dT (Sigma-Genosys) and 10 units of ribonu-
clease inhibitor (Invitrogen). Gene expression was measured by
real time PCR (RT-PCR) using the Corbet Research Rotor gene
6000 with the QuantiTech SYBR Green kit (QIAGEN). The FOXP3
sequences used were: forward primer 5′-ACCTGGAAGAACGCCAT
and reverse primer 5′-TGTTCGTCCATCCTCCTTTC both at a ﬁnal
concentration of 0.4 M.  FOXP3 copy numbers were expressed in
relation to human acidic ribosomal protein (HuPO), the house keep-
ing gene.
The standards were prepared as above using blood donated by
an adult and the RT-PCR product pooled and puriﬁed using the
QIAquick PCR Puriﬁcation kit (QIAGEN). The DNA was  then quanti-
ﬁed using the nanodrop and FOXP3 copy numbers calculated using
the Avogadro constant formula.
Statistical analyses: For paired comparisons between two time
points random effects models were used to allow for the cluster-
ing effect of subject. For the antibody responses where there were
7 time points a generalised estimating equation was used with an
exchangeable correlation structure. Responses were appropriately
transformed and in the absence of a suitable transformation the
data was  ranked. All regressions were adjusted for possible con-
founding affects of sex, but due to well balanced groups there was
very little evidence of confounding. Where appropriate, time and
dose group interactions were tested. Signiﬁcance was measured at
the 5% level and all analyses were performed in Stata 11 (Statacorp)
and ﬁgures drawn using Matlab 7.9 (The MathWorks Inc.).














(Fig. 1. The design of the study, the number of children vaccinated and bled at
. Results
.1. Recruitment and participation
The  number of participants and their loss to the study at dif-
erent time points are shown in Fig. 1. The overall refusal rate was
1.5%, loss to follow up due to the participant travelling was 17.4%
nd 3.8% of the children received an unscheduled measles vaccine.
.2. Safety
The two dose regimen was safe since side effects were mild
nd infrequent. They did not differ in frequency or timing between
roup 1 and group 2 either at 4 months of age or at 9 months of
ge. The most frequent complaints were diarrhoea and fever with
 mean prevalence of 7.9 ± 2.4% and 6.6 ± 2.7% respectively.
.3.  Measles and other antibodyBefore  vaccination at 4 months of age median HAI titres were
og2 2 (IQR 0–3) and log2 3 (IQR 1–4) in groups 1 and 2 respectively
Fig. 2 and Supplementary Table). At 9 months before the second time point and the immunological tests undertaken are shown in this ﬁgure.
measles  vaccination the median HAI titre in group 2 was  log2 3
(IQR 1–6) which is signiﬁcantly higher than that of group 1 which
was zero; 77% of group 2 children had detectable antibody and 66%
had protective levels whereas antibody was  detected in only 6% of
group 1 children. Two weeks after the second dose of E-Z vaccine
antibody titres had risen sharply in group 2 with all but one child
reaching protective levels whereas only 25/65 (36.4%) of group1
children attained these levels after their ﬁrst measles vaccination.
At  18 months of age antibody titres in group 2 (median 4, IQR
3–5) fell signiﬁcantly lower than those in group 1 (median 6, IQR
5–7) but then stabilised between 18 and 36 months. Both groups
responded sharply to booster vaccination reaching equivalent and
high concentrations (median titre 9, IQR 8–10). At 48 months of
age antibody titres had dropped fourfold in group 1 (median 7,
IQR 6–8) and eightfold in group 2 (median 6, IQR  5–6) although
all subjects had protective levels of antibody. Responses did not
vary signiﬁcantly by sex.
In  group 2 pre-vaccination antibody titres at 4 months were neg-
atively and signiﬁcantly correlated with titres at 9 and 18 months.
Antibody titres at 18 and 36 months were positively and signif-
icantly correlated with those at 36 and 48 months respectively
(Table 1).















HFig. 2. Measles haemaglutination-inhibiting antibody titres at various time
Hepatitis B and Tetanus antibody measured at 18 months of
ge did not differ signiﬁcantly between the two groups (data not
hown).
.4. Effector cell IFN- responses to measles or measles peptides
Table  2 shows the net number of IFN- ELI spots at different
imes of the study. At no time did the median numbers differ signiﬁ-
antly between the groups nor was there a signiﬁcant rise following
 booster dose of the vaccine. However there was a signiﬁcant fall
n both groups between 36 and 48 months of age (p < 0.0001 in both
ases).
Responses to pooled fusion peptides were low but rose signiﬁ-
antly following the booster dose of measles vaccine at 36 months
f age (p = 0.001 and p < 0.001 for group 1 and 2 respectively).
able 1
orrelation of pre and post vaccination HAI titres in group 2.
Age (months) 9 9.5 
4 r −0.48 −0.45 
p 0.0002 0.021 
n 56 26 
9 r  0.48 
p 0.01 
n 26 
9.5  r 
p 
n
18  r 
p 
n 
36  r 
p 
n 
36.5  r 
p 
n 
, spearman correlation; p, p-value; n, number of subject pairs.
ighlighted  p-values are those signiﬁcant after correction for multiplicity.s during the study. p-Values for differences between the groups are shown.
There was  no signiﬁcant correlation between antibody titres and
effector responses to either virus or peptides at any time point (data
not shown). Effector responses did not vary signiﬁcantly by sex.
3.5. Measles-speciﬁc memory-cell responses
Table 3 shows the net IFN- ELIspot responses after 10 days
of stimulation of PBMC with measles virus or pooled measles pep-
tides. At 9 months of age responses of unvaccinated children (group
1) to pooled NP peptides were signiﬁcantly lower than those in
group 2 who  had received E-Z vaccine at 4 months of age (p = 0.002).
Thereafter there were no signiﬁcant differences in cultured mem-
ory responses to the virus or peptides at 18 or 48 months of age.
At no point did memory ELIspot responses correlate with measles
antibody titres (data not shown) nor did they vary by sex.
18 36 36.5 48
−0.40 −0.06 0.20 −0.18
0.0023 0.65 0.18 0.25
56 52 47 42
0.29 0.24 0.19 0.40
0.04 0.09 0.22 0.0085
53 49 45 42
0.26 −0.01 0.28 −0.04
0.19 0.97 0.17 0.87
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Table 2
IFN-  ELIspot effector responses (expressed as net SFU per 106 PBMC) in the two groups at various ages.















































I48  Fusion peptides 
.6. Plasma cytokines
Levels  of IL-10, lL-2R, IFN- and MIP-1 in plasma were mea-
ured before and two weeks after the booster dose of E-Z vaccine at
6 months of age (Table 4). In the case of IL-2, IL-5, IL-13 and IL-12
40 levels were generally undetectable and data were not analysed.
here were no signiﬁcant differences between the groups at either
f the time points nor did they vary by sex. The booster vaccination
esulted in a signiﬁcant fall in IL-10, IL-2R and  MIP-1 levels  in
oth groups (p < 0.001).
.7. FOXP3 expression
There  were no signiﬁcant differences in FOX P3 expression (nor-
alized against HUPO) between the groups or within the groups
efore or two  weeks after the booster vaccination at 36 months of
ge. Before the boost median levels were 19.0 (IQR 3.7–39.0) and
3.6 (IQR 6.5–48.9) copies per mL  for group 1 (n = 37) and group 2
n = 39) subjects respectively. Two weeks afterwards median levels
ere 9.3 (IQR 2.8–26.6) and 20.4 (IQR 6.2–38.7) copies per ml  for
roups 1 and 2 respectively..8.  Flow cytometry for cytokine producing T-cells
Percentages of CD8 or CD4 T-cells expressing IFN-, CD69 or
oth markers in negative control cultures were subtracted from
able 3
FN-  memory responses (expressed as net SFU per 106 PBMC) in the two groups at vario
Age (months) Stimulus 
9 NP peptides 
18  E-Z virus 
18  NP peptides 
48  E-Z virus 





those  in stimulated cultures. A net value of >0.1% was considered
positive (Table 5).
Memory  cell assay at 9 months: Only samples from group 2 infants
were tested. In the majority of samples IFN- and CD69 responses
to the nucleoprotein peptide pool were detectable in CD4 but not
in CD8 T-cells.
Effector cell assay at 9.5 months of age: A similar but low propor-
tion of CD4 and CD8 T-cells from the two  groups showed a positive
IFN- response after stimulation with E-D virus. There was  concur-
rence of CD4 and CD8 IFN- responses in 6 of 7 samples. Expression
of CD69 was detected more often in CD8 than CD4 T-cells.
Memory cell assay at 18 months: After stimulation with EZ virus
IL-2 expression was detectable in less than half of the samples
and very few expressed IFN-. There were no signiﬁcant differ-
ences between cell types and little concurrence within the positive
samples.
4. Discussion
Measles antibody protects against infection but its role in lim-
iting viral multiplication and severity of disease is less clear [16].
Although an arbitrary protective level of measles antibody has been
ascribed, in an outbreak of measles in Senegal half of the anti-
body negative vaccinated children did not develop measles when
exposed [12]. In vaccinated macaques a rapid amnestic antibody
response follows measles infection which coupled with a boost in
us times of the study.
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Table  4
Cytokine levels (pg/mL) pre and post a booster dose of E-Z measles vaccine at 36 months of age.
Cytokine Time Group Median Lower quartile Upper quartile n
IFN Pre 1 60.2 0 102.0 50
Post 1 26.1 0 63.1 50
Pre 2 31.8 0 172.6 55
Post 2 38.1 0 85.8 55
IL-10 Pre 1 0.9 0.2 2.0 50
Post 1 0 0 0.8 50
Pre 2 0.7 0 1.7 55
Post 2 0 0 0.5 55
IL-2R Pre 1 207.5 94.8 331.3 50
Post 1 64.2 38.5 115.6 50
Pre 2 175.1 0 380.7 55
Post 2 55.2 21.8 85.5 55






















CPost 1 3.7 
Pre 2 10.8 
Post 2 5.1 
ell mediated immunity limits viral replication and aborts disease
17]. With the assumption that a booster dose of vaccine mimics
nfection or exposure, we examined both antibody and cell medi-
ted responses shortly after re-vaccination.
Our study is the ﬁrst to provide detailed knowledge of the early
ntibody response to a booster dose of measles vaccine following
ither vaccine schedule. A standard dose of E-Z vaccine in 4 month
ld infants raised protective levels of antibody in the majority of
he children by 9 months of age. After either one or two  booster
oses of vaccine antibody concentrations rose dramatically within
 weeks and faded slowly with time. Maternal antibody, possibly by
eutralising the live vaccine and altering antigen processing [18],
epressed both primary and secondary antibody responses. The
mpact faded by 36 months of age and did not inﬂuence responses
o further vaccination. The booster responses were independent of
ntibody at the time of vaccination suggesting that even if antibody
oncentrations are low a rapid response in conjunction with cellu-
ar immune responses will limit disease and lower transmission
n subsequent measles exposure [19]. However concentrations of
ntibody following a boost decayed quicker in group 2 children.
able 5
umbers and percentages of individuals with responses to measles detectable by ﬂow cyt





Markers CD8 T-cells 
Undetectable 
9 Memory response 10
days  measles peptide
Yes IFN 9 
CD69  9 
CD69  + IFN 9 
9.5 Effector response 18 h
E-D measles virus
stimulation
Yes IFN 14 
CD69  12 
CD69  + IFN 16 
No IFN 13 
CD69  13 
CD69  + IFN 14 
Combined IFN 27 
CD69  25 
CD69  + IFN 30 
18 Memory response 10
days  E-Z measles virus
stimulation
Yes IFN 6 
IL-2  5 
IFN  + IL-2 7 
No IFN 8 
IL-2  5 
IFN+  IL-2 8 
Combined IFN 14 
IL-2  10 
IFN+  IL-2 15 0 11.3 50
0 21.6 55
0 12.0 55
They  may  be more susceptible to subclinical infections [20] though
this event is unlikely to result in the further spread of measles [21].
CD8 T-cells are necessary to control measles viraemia [16] and
the role and importance of cytotoxic T-cell responses, cellular
proliferative responses and cytokine responses during and after
measles or primary vaccination have been thoroughly described
[15,22,23]. However, very little is known of these responses shortly
after booster vaccination or natural exposure in immunized chil-
dren.
Early measles vaccination primed IFN- memory T-cell
responses to nucleoprotein peptides which were signiﬁcantly
greater at 9 months of age in immunized than unimmunized
infants. However some of the unimmunized infants in group 1
had responded to these peptides suggesting that common infec-
tions such as cytomegalovirus or Epstein-Barr virus prompt such
responses [24]. At 18 and 48 months of age IFN- memory
responses were readily detectable and similar in the two groups of
children. Maternal antibody had no effect on these responses nor
were they inﬂuenced by the number of times the child had been
immunized.
ometry. Statistics based on comparison between expression of markers by CD4 and
CD4 T-cells p
Detectable % detectable Undetectable Detectable % detectable
2 18 1 10 91 0.002
2 18 2 9 82 0.009
2 18 4 7 64 NS
4 22 14 4 22 NS
6 33 17 1 6 NS
2 11 17 1 6 NS
3 19 13 3 19 NS
3 19 14 2 13 NS
2 13 15 1 6 NS
7 21 27 7 21 NS
9 26 31 3 9 NS
4 12 32 2 6 NS
1 14 6 1 14 NS
2 29 6 1 14 NS
0 0 7 0 0 NS
0 0 7 1 13 NS
3 38 5 3 38 NS
0 0 8 0 0 NS
1 7 13 2 13 NS
5 33 11 4 27 NS
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Surprisingly ex vivo measles IFN- effector responses two weeks
fter vaccination did not differ between those receiving primary
accination (group 1) or secondary vaccination (group 2). After a
urther boost at 36 months of age effector responses to E-Z virus
ere similar in both groups and in neither group was  there a rise
fter the boost. However there was a small but signiﬁcant rise to
usion peptides which did not differ between the groups.
Prime  boost studies using recombinant Modiﬁed Vaccinia
nkara/TB vaccines in man  [25] and DNA/measles vaccines in mon-
eys [17] indicate that maximum IFN- ELIspot responses occur
–2 weeks after the booster immunization. Thus we  are conﬁ-
ent that the lack of a response after the booster doses was  real
nd not due to late sampling. However macaques primed with
NA/measles protein vaccines raise cytotoxic T-cell, IFN- and
ntibody responses within 14 days of challenge with live virus
17,26]. Perhaps in our study the attenuated vaccine virus did not
ultiply sufﬁciently in the presence of antibody to raise a cell medi-
ted immune response.
There  were no signiﬁcant differences in plasma cytokine lev-
ls between the groups before or after the 36 month booster dose
hich resulted in a signiﬁcant fall in IL-10, IL-2R and MIP-1 con-
entrations in both groups after the boost. This was  not mirrored
y changes in FOXP3 mRNA expression which were expected to
ncrease [27].
We  found no relationship between maternal or vaccine derived
easles antibody concentrations and IFN- ELIspot numbers or
ytokine levels after primary or secondary immunization. Similar
ndings have been noted following primary measles immunization
n infants [23] or after secondary immunization in children [28] or
fter measles in children [29].
Intracellular cytokine staining showed that CD4 and CD8 T-cells
ere equally prominent producers of IFN- during the effector
esponse and that both cell types a produced IL-2 in memory
esponses. The memory response at 9 months of age following early
accination consisted predominantly of CD4 T-cells. The ﬁnding ﬁts
ith the idea that a Th-1 type response is predominant following
accination [28] but contrasts with previous studies of cytotoxic
-cell activity during measles or after vaccination which reveal this
esponse to be mainly due to CD8 T-cells [30]. Stimulation with 20-
er  rather than shorter peptides may  have favoured a CD4 T-cell
esponse particularly in very young children.
Early two  dose schedules of measles vaccine given at 6 and 9
onths of age were recommended by WHO  to control outbreaks
nd for use in countries with high attack rates of measles in infancy.
ow WHO  recommends such schedules in areas with a high inci-
ence of HIV and measles [31]. However once measles is controlled
n endemic areas the proportion of vaccinated mothers who have
ow levels of measles antibody will increase along with the pro-
ortion of unprotected infants. At present such children can only
e protected by raising herd protection by supplemental measles
accinations. Others have argued that if measles is to be eliminated
nd ultimately eradicated it would be better to strengthen routine
ervices to achieve high coverage before deploying mass immu-
ization [32,33]. An early two dose schedule would ﬁt well into
his scheme: it protects the very young [5] and the HIV infected
34], increases coverage [4] and enhances child survival [6]. Addi-
ional doses could be given if outbreaks occur or if measles is to be
liminated or eradicated.
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